Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
Status:
Completed
Trial end date:
2022-02-24
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single center, randomized, two-period crossover study in healthy male and
female subjects designed to evaluate the relative bioavailability (BA) and safety at steady
state of two formulations of nimodipine: GTX 104 (nimodipine for intravenous [IV] infusion;
test formulation) and nimodipine oral capsules, RS (reference formulation).